Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$141.59 USD

141.59
188,301

+1.16 (0.83%)

Updated Sep 22, 2025 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Medical Instruments Stocks Likely to Beat Estimates in Q4

by Zacks Equity Research

Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.

Zacks Equity Research

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.

Zacks Equity Research

Why Masimo (MASI) Could Beat Earnings Estimates Again

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Stock Market News For Jan 10, 2019

by Zacks Equity Research

Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.

Zacks Equity Research

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Zacks Equity Research

Here's Why Investors Should Hold Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

Zacks Equity Research

Masimo (MASI) Down 3.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

by Zacks Equity Research

DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.

Zacks Equity Research

Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes

by Zacks Equity Research

Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.

Zacks Equity Research

Medtronic Moves a Step Ahead With Mazor Robotics Buyout

by Zacks Equity Research

Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.

Zacks Equity Research

Hill-Rom Rides on New Products, Asia Pacific Sales Drop

by Zacks Equity Research

Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.

Zacks Equity Research

GNC Holdings Domestic Revenues Soft, Global Growth Strong

by Zacks Equity Research

Within same store, GNC Holdings (GNC) disappoints on the domestic franchise locations front. However, its steadily thriving international business is a big boon.

Zacks Equity Research

Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?

by Zacks Equity Research

Medtronic (MDT) poised to gain on continued RTG business growth in Q2.

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.

Zacks Equity Research

Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up

by Zacks Equity Research

Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

by Zacks Equity Research

Solid fiscal Q4 for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

Zacks Equity Research

ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line

by Zacks Equity Research

Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.

Zacks Equity Research

Haemonetics Strong on Plasma & Hemostasis Management Units

by Zacks Equity Research

Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.

Zacks Equity Research

NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure

by Zacks Equity Research

NuVasive (NUVA) adopts initiatives to boost the U.S. Spinal Hardware unit.

Zacks Equity Research

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.

Zacks Equity Research

Bio-Rad Clinches USDA Contract, Boosts Life Science Segment

by Zacks Equity Research

Bio-Rad (BIO) adopts initiatives to boost Life Science unit.

Zacks Equity Research

BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems

by Zacks Equity Research

BD's (BDX) diagnostics portfolio boasts tests used for rapid susceptibility testing.

Zacks Equity Research

ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout

by Zacks Equity Research

MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.

Zacks Equity Research

Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive

by Zacks Equity Research

Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.

Zacks Equity Research

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?